Compare iShares Bitcoin Trust (IBIT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Incyte Corporation — how do they compare? iShares Bitcoin Trust trades at $35.9, while Incyte Corporation trades at $120.85 (market cap $24.54B). The key difference: Incyte Corporation is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| IBIT | INCY | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $71.29 | $129.93 |
52-Week Low | $33.29 | $81.61 |
Market Cap | — | $24.54B |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $36.24, showing minimal daily movement with a 0.01% gain. Technical indicators signal a bearish trend with moving averages in sell territory, though oscillators remain neutral. The stock faces resistance at $37 and finds support at $36. Recent news highlights institutional interest in crypto ETFs, with BlackRock's digital assets head noting 'overwhelming demand' (Bloomberg, August 10, 2026).
The outlook remains cautious due to bearish technical signals and Bitcoin's 50% decline from 2025 peaks. Long-term potential exists via institutional adoption, but near-term risks include crypto market volatility and selective ETF inflows. Investors should weigh technical weakness against BlackRock's growing ETF footprint.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
